Symposium 3: Fasting plasma glucose, HbA1c or oral glucose tolerance test: should we use the three tests to evaluate the patient?
DOI:
https://doi.org/10.47196/diab.v56i3Sup.496Keywords:
diabetes mellitusAbstract
The objective of the presentation will be to answer , based on some evidences,referred to the eventual additive contributions of the three tests with Progession to Diabetes (PDMT2) and/or exposure to Cardiovascular Risk (CVR) or Chronic Renal Disease (CRD) and how we can use them from a clinical perspective.
In prediabetes definition there are no discrepancias regarding to Impaired Glucose Tolerance (IGT), but they are obvious regarding Impaired Fasting Glucose (IFG) = American Diabetes Association criteria : 100-125 mg/dl an World Health Organization : 110-125 mg/dl. There no agreement also for “intermediate” HbA1c cutoffs = (HbA1c(5.7-6.4%)) for American Diabetes Association and (HbA1c(6.1-6.4%)) in UK (NICE). These divergences have different risk of progression and also the pathophysiological contributions of each of the evaluations could be complementary.
References
I. Richter B. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia. Cochrane Database of Systematic Reviews 2018;10 (10)CD012661.
II. Menke A. Diabetes based on 2-h plasma glucose among those classified as having prediabetes based on fasting plasma glucose or A1c. Diabetes & Vascular Disease Research 2018;15;46-54.
III. Xiaoyan C. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ 2020;370:m2297.
IV. Diurlin S. Persisting prediabetic conditions and glomerular filtration rate. A longitudinal study. Primary Care Diabetes 2022. doi: 10.1016/j.pcd.2022.05.013.
V. Sinha A, et al. Association of fasting glucose with lifetime risk of incident heart failure: the Lifetime Risk Pooling Project. Cardiovasc Diabetol 2021;20(1):66.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 on behalf of the authors. Reproduction rights: Argentine Diabetes Society
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
